By Brazil Stock Guide – Rede D’Or São Luiz S.A. (RDOR3) has become one of Brazil’s clearest valuation debates: a high-quality healthcare company trading at a discount, but still not cheap enough to make investors forget the country risk. In a May 18 sector note, BTG Pactual said Rede D’Or was the most debated company during a recent non-deal roadshow in Europe, as investors reassessed the stock after its recent weakness and more cautious views following quarterly results.
BTG said Rede D’Or’s operating momentum remains “steady as she goes,” with healthy execution in both hospitals and its health-plan business. The issue, in its view, is less about the company’s fundamentals and more about timing, macro uncertainty and technical pressure on the stock.
The valuation argument is now easier to make. BTG said Rede D’Or trades at roughly 15 times blended forward earnings, about a 20% discount to its historical valuation range of 18 to 19 times earnings. The bank also noted that part of the recent de-rating appears linked to the stake reduction by GIC, whose position fell to 12.75%, from above 17% previously.
That overhang matters. Even investors who agree with the operational thesis may hesitate to build larger positions if they believe a reference shareholder could continue to reduce exposure. According to BTG, some investors explicitly said they would feel more comfortable adding to the stock once that technical pressure becomes clearer.
Consensus still positive
The broader analyst community remains mostly constructive. Rede D’Or’s investor relations page lists coverage by major banks including BTG Pactual, Itaú BBA, Santander, Safra, Jefferies, JPMorgan, Morgan Stanley, Goldman Sachs, Citi, UBS, Bradesco BBI and Bank of America, underscoring how closely watched the stock remains among Brazil healthcare names.
Santander, for example, cut its 2026 price target for Rede D’Or to R$ 51.00, from R$ 55.50, but kept an outperform recommendation. The bank cited lower estimates and a slightly higher cost of capital, while still arguing that the stock’s underperformance had created an interesting entry point for investors.
Safra also keeps a positive view. The bank sees Rede D’Or benefiting from hospital expansion, higher-complexity procedures and the maturation of assets such as Atlântica D’Or, which it said already represents about 16% of the company’s 10,351 operational beds. Safra’s analysis points to a roughly 5% increase in operational beds over five years, supporting earnings growth in the hospital division.
The Brazil discount
The tension is that the stock’s discount is not happening in a vacuum. RDOR3 has been trading around the mid-R$ 30s, showing an intraday range of R$ 33.95 to R$ 34.39. The stock was down 15.79% year to date, even as it remained slightly positive over 12 months.
BTG said the hesitation to “pull the trigger” is tied to Brazil’s political and macro uncertainties, higher-for-longer interest rates and doubts about the sustainability of the labor-market backdrop. In private healthcare, that matters because employment, disposable income and corporate benefit plans remain key supports for demand.
Leave a Reply